A Randomized, 12-Week, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of Plecanatide (3.0 and 6.0 mg) in Patients With Chronic Idiopathic Constipation (The CIC3 Study)

Trial Profile

A Randomized, 12-Week, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of Plecanatide (3.0 and 6.0 mg) in Patients With Chronic Idiopathic Constipation (The CIC3 Study)

Completed
Phase of Trial: Phase III

Latest Information Update: 05 Jun 2018

At a glance

  • Drugs Plecanatide (Primary)
  • Indications Constipation
  • Focus Registrational; Therapeutic Use
  • Acronyms CIC3
  • Sponsors Synergy Pharmaceuticals Inc
  • Most Recent Events

    • 05 Jun 2018 Results (n=2683) data from two phase 3 clinical studies (CIC3 and National CIC3), presented at the Digestive Disease Week 2018.
    • 24 May 2017 Results (n=2683) assessing impact of Plecanatide on quality of life for patients with chronic idiopathic constipation using patient data from two phase 3 clinical studies (CIC3 and National CIC3), presented at the 22nd Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research
    • 09 May 2017 Results (n=3536) assessing placebo relative effect of Linaclotide and Plecanatide on efficacy and safety using patient data pooled from 4 phase 3 trials (NCT00730015, NCT00765882, NCT01982240, NCT02122471), presented at the Digestive Disease Week 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top